Organization Overview
Alternative names
acetylcysteine (mucomyst) (2 trials)
dabrafenib (tafinlar) (1 trial)
Acquired Immunodeficiency Syndrome (Phase 1)
Albinism (Phase 2)
Albinism, Oculocutaneous (Phase 2)
Alkaptonuria (Phase 2)
Aphasia, Primary Progressive (Phase 2)
Ataxia (Phase 1)
Cerebellar Ataxia (Phase 1)
Chromosome Deletion (Phase 1)
Cystinosis (Phase 2)
Developmental Disabilities (Phase 1)
Disease (Phase 1)
Distal Myopathies (Phase 2)
Erdheim-Chester Disease (Phase 2)
Fibrosis (Phase 2)
Frontotemporal Dementia (Phase 2)
Gangliosidoses (Phase 2)
Gangliosidosis, GM1 (Phase 2)
Growth Disorders (Phase 2)
Hermanski-Pudlak Syndrome (Phase 2)
HIV Infections (Phase 1)
Immunologic Deficiency Syndromes (Phase 1)
Infections (Phase 1)
Intellectual Disability (Phase 1)
Melanoma (Phase 1)
Metabolic Diseases (Phase 2)
Metabolism, Inborn Errors (Phase 2)
Mitochondrial Diseases (Phase 2)
Muscular Diseases (Phase 2)
Nervous System Malformations (Phase 2)
Niemann-Pick Diseases (Phase 2)
Niemann-Pick Disease, Type A (Phase 2)
Niemann-Pick Disease, Type C (Phase 2)
Ochronosis (Phase 2)
Parasomnias (Phase 1)
Pick Disease of the Brain (Phase 2)
Platelet Storage Pool Deficiency (Phase 2)
Proteus Infections (Phase 2)
Proteus Syndrome (Phase 2)
Pulmonary Fibrosis (Phase 2)
Sarcoma (Phase 1)
Sarcoma, Kaposi (Phase 1)
Self-Injurious Behavior (Phase 1)
Severe Combined Immunodeficiency (Phase 1)
Sleep Disorders, Circadian Rhythm (Phase 1)
Sleep Wake Disorders (Phase 1)
Smith-Magenis Syndrome (Phase 1)
Spinocerebellar Ataxias (Phase 1)
Spinocerebellar Degenerations (Phase 1)
Syndrome (Phase 2)